发布时间：2026-03-12 10:40 Highlights

Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissions
Bespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resilience
Partnership aligns with the science-based climate commitments of both companies
PARMA, Italy & HOLMES CHAPEL, England--(BUSINESS WIRE)--Chiesi Group("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, andBespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership,increasing pressurized metered dose inhaler(pMDI)manufacturing capacityat Bespak’s Holmes Chapel site to
=*=*=*=*=*=
当前为第1/9页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页